In-article:

Abionyx Pharma: recruitment completed for a study


(CercleFinance.com) – Abionyx Pharma announces that the last patient has been enrolled in the phase 2a clinical study evaluating CER-001, Bio-HDL, as a potential treatment for patients with sepsis at high risk of developing a lesion acute kidney.

This study under the name RACERS evaluates the safety and efficacy of CER-001 administered intravenously to patients in intensive care. A total of 20 patients will be randomized to receive eight doses of CER-001 or placebo over six days.

The clinical study is being conducted in partnership with the University of Bari, in southern Italy. The biotech company reconfirms that final key results will be reported by late fall 2022.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85